Our last newsletter

Facebook
Google+
http://www.inovotion.com/publications/newsletter">
Twitter
LinkedIn
Inovotion - Newsletter May 2019

Newsletter May 2019

New Cancer model for in vivo efficacy evaluation in the chicken embryo model: effect of cytarabine on the acute myeloid leukemia (AML) cell line MV4-11

INOVOTION’s R&D Team continuously develops new models, with our latest fully validated offering featuring the MV4-11 AML cell line and treatment with Cytarabine.

Thanks to INOVOTION’s line-up of fast, reliable and cost-effective models, the scientific community can now rely on a robust in vivo screening technology platform to validate early and select the most promising compounds to further invest on.

Acute Myeloid Leukemia (AML) is a type of blood cancer often associated with a poor prognosis. About 1 million AML cases were diagnosed in 2015 worldwide. Because of its poor outcome, the challenge of finding new treatments for this disease is all the more important. Nowadays, a treatment protocol including Cytarabine is commonly used for this pathology, with over 500 clinical trials being conducted with Cytarabine in 2019, usually in combination with other agents.

Download the brochure
 

A real in vivo model without regulatory constraints.

INOVOTION's model helps you to save time and avoid approval issues from ethics committees.

The European Directive 2010/63/EU on the protection of animals used for scientific purposes and French Regulations (Code Rural R214-89 to R214-137, last modified in 2013) covers the use of chicken embryos starting at Day 18 of development (E18). Thus, there are no ethical constraints for us since all our studies are stopped at Day 18.

Concerning US regulations, according to the NIH, avian organisms are considered as “live vertebrate animals” only after hatching. As such, the use of chicken embryos does not need to be reviewed or approved by Institutional Animal Care and Use Committees (IACUC).

Furthermore, INOVOTION’s novel technology platform could dramatically reduce the use of rodents in oncology discovery.

Get more info here
 

Presentation by Jean Viallet, PhD, Inovotion’s Founder, on Anti-PD-1/Anti-PD-L1 therapies at the Meet2Win conference.

On May 22, during the Meet2Win convention (Bordeaux, France), Jean Viallet, Ph.D., CEO and Founder of INOVOTION was giving a talk on the theme “New therapeutic approaches based on Anti-PD1/anti PD-L1 combinations”.

Therapeutic strategies based on Anti-PD-1/Anti-PD-L1 are becoming increasingly important. Although monoclonal antibodies targeting PD-1 and PD-L1 are currently considered standard of care, a plethora of new approaches involving combinations with other molecules show great potential. INOVOTION has developed efficient, reliable and affordable assays for testing Anti-PD-1 and Anti-PD-L1 based therapies.

 

AIS 2019: INOVOTION will give a talk and introduce latest developments in in vivo efficacy and safety screening. Visit us at the poster session to learn more about efficient in vivo assays.

On June 24, during the 7th AIS event, Arnaud Peyronnier will give a presentation on “Unique in vivo model for assessing the efficacy of antibodies”. This talk will be given at 4:30 PM and will present the advantages of the chicken embryo’s chorioallantoic membrane model for the study of antibody-based treatments and how Inovotion’s models can generate fast, reliable and robust in vivo data.

Link to the event
 

Latest developed cell lines

Since January 2019, we validated 6 cell lines on the chicken embryo model:

- MV4-11 (acute myeloid leukemia)

- 143B (osteosarcoma)

- MNNG (osteosarcoma)

- SK-MEL-28 (melanoma)

- A427 (carcinoma)

- HPAF-II (adenocarcinoma)

You can get our portfolio of 46 validated cell lines below:

Download our portfolio
 

Events – Where to meet us

US

BIO International Convention
Philadelphia, June 3 – 6

 

Europe

 

7th Antibody Industrial Symposium
Tours, France, June 24 – 25

 
 
 

Who we are

Because we know that one of your main preoccupations is to optimize your preclinical and discovery studies, INOVOTION has developed a unique and cutting-edge in vivo technology.

As a Contract Research Organization (CRO) dedicated to in vivo evaluation for drug discovery, particularly in oncology, INOVOTION is a sought-after partner for drug discovery Pharma and Biotech companies as well as academic labs all over the world.

Our main missions are to:

  • Help you find the best anticancer candidate anti-cancer treatment
  • Detect the first in vivo toxicity effects of your candidate compounds
  • Improve the productivity and return-on-investment of your preclinical and discovery process by maximizing your lead optimization phase

Accelerate the overall drug discovery process to answer unmet medical needs in oncology.

Any questions about Inovotion's technology? Visit our F.A.Q.!

Efficacy evaluation
 

Target validation
 

Toxicity evaluation
 

Multi-cancer screening

INOVOTION SA
HQ & lab facilities

+33 475 549 512

5 Avenue du grand Sablon
38700 La Tronche
France

INOVOTION Inc.

185 Alewife Brook Parkway, Suite 210
Cambridge, MA 02138, USA

Facebook
Google+
http://www.inovotion.com/publications/newsletter">
Twitter
LinkedIn

Register for our Newsletter